Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication

NEXT STORY
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors
PREV STORY
RadNet Announces a Proposed Refinancing Transaction for its $611 Million Senior Secured Term Loan and $195 Million Senior Secured Revolving Credit Facility
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aclaris Therapeutics Reports Third Quarter 2015 Financial Results

MALVERN, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage ...

author_avatar
NASDAQ Market News

Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

RICHMOND HILL, Ontario, July 25, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) ...

author_avatar
NASDAQ Market News

NASH clinical trial presentation and continued revenue growth

Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the ...

author_avatar
NASDAQ Market News